Insmed (NASDAQ:INSM) Given New $139.00 Price Target at Truist Financial

Insmed (NASDAQ:INSM – Get Free Report) had its price objective boosted by Truist Financial from $126.00 to $139.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Trui…

Read Full Article →